IGF1R and cancer: Several therapeutic mAbs directed against IGF-1R have been developed, and encouraging preclinical outcomes have been observed with figitumumab (IgG2a, phase III) [42,43,44], ganitumab (IgG1, phase III) [45,46,47], dalotuzumab (IgG1, phase III) [48,49], teprotumumab (IgG1, phase II) [50,51], cixutumumab (IgG1, phase II) [52,53], robatumumab (IgG1, phase II) [54,55], and BIIB022 (IgG4, phase I) [56] in many malignant tumors.